Peptide
Retatrutide
Retatrutide is used or studied for extreme weight loss (trials) and related fat loss and metabolic health goals. Potential benefits and safety depend on indication, formulation, dose, and medical supervision.
In depth
How it works
Retatrutide is an investigational triple agonist that activates the GIP, GLP-1, and glucagon receptors together. Adding glucagon-receptor activity to the GIP/GLP-1 combination is intended to increase energy expenditure alongside the appetite and insulin effects shared with other incretin drugs.
What the research shows
A Phase 2 trial published in NEJM reported body weight reductions of up to roughly 24% at 48 weeks with the highest dose tested, among the largest effect sizes reported for any obesity medication in a controlled trial. Later Phase 3 readouts (TRIUMPH program) reported weight loss extending to around 28% at 68 weeks.
Retatrutide remains investigational — no FDA approval exists yet, and it is not available by prescription. Reported adverse events follow the same pattern as other incretin-based drugs: gastrointestinal symptoms, most common during dose escalation.
Detail
Overview
Retatrutide is used or studied for extreme weight loss (trials) and related fat loss and metabolic health goals. Potential benefits and safety depend on indication, formulation, dose, and medical supervision.
Benefits, side effects, and protocols
Benefits list
- Extreme weight loss (trials)
Side effects
- GI effects
Vendor protocol
- None listed
Clinical protocol
- None listed
Evidence
- Low
- Phase III trials
Regulatory
- Not Fda Approved
Research
Mechanisms
Evidence notes
- Low
- Phase III trials
Administration
Research links
Contraindications
- None listed
Components
- None listed
Regulatory data
- Not Fda Approved
Aliases
- None listed
Related compounds
Guides that cover Retatrutide
Terminology on this page
Concepts from the glossary that come up around Retatrutide.
Glucagon-like peptide-1 — an incretin hormone that increases insulin secretion, slows gastric emptying, and reduces appetite.
The hormone that raises blood glucose — and, at the receptor level, a target for increasing energy expenditure.
A single molecule activating three receptors — retatrutide targets GLP-1, GIP, and glucagon receptors.
A compound under study in clinical trials but not yet approved for marketing.
Community abbreviations for semaglutide, tirzepatide, retatrutide, and cagrilintide.
Frequently asked questions
Is retatrutide FDA approved?
No. Retatrutide is still in clinical trials and is not FDA approved or available by prescription.
What makes retatrutide different from semaglutide or tirzepatide?
Retatrutide adds glucagon-receptor agonism on top of the GIP and GLP-1 activity that tirzepatide already combines, making it a triple agonist. Early trial data has shown larger average weight loss than either semaglutide or tirzepatide, though it has not yet completed the regulatory approval process.
Educational reference only. Pepperz does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing recommendations. Sourcing Retatrutide? Check your source before you use anything.